澳洋健康公告称，2025年9月15日，悦升科技与澳洋集团签署协议，澳洋集团将1.53亿股（占比20%） 转让给悦升科技，同时放弃5%表决权。11月6日，股份过户登记完成。本次权益变动后，控股股东由澳 洋集团变更为悦升科技，实际控制人由沈学如变更为张家港经开区管委会。财务顾问东吴证券核查认 为，本次权益变动实施程序合规，相关方依法规范运作，收购人履行承诺且未违反后续计划，公司未为 收购人及其关联方提供担保或借款。 ...

东吴证券股份有限公司 关于 江苏澳洋健康产业股份有限公司 详式权益变动报告书 东吴证券股份有限公司（以下简称"本财务顾问"）接受悦升科技的委托， 担任其本次权益变动的财务顾问。2025年9月16日，上市公司公告了《详式权益 变动报告书》。根据《上市公司收购管理办法（2025年修正）》第七十一条， 本财务顾问持续督导期为2025年9月16日至收购完成后12个月。澳洋健康于2025 年10月31日披露了2025年三季度报告。根据《上市公司收购管理办法》等法律 法规的规定，通过日常沟通，并结合澳洋健康定期报告，本财务顾问出具本持 续督导意见。 本持续督导意见不构成对上市公司的任何投资建议；投资者根据本持续督 导意见所做出的任何投资决策而产生的相应风险，本财务顾问不承担任何责任。 本财务顾问未委托或授权其他任何机构或个人提供在本持续督导意见中列载的 信息和对本持续督导意见做任何解释或者说明，同时本财务顾问提请投资者认 真阅读上市公司发布的2025年三季度报告及其他信息披露文件。 释义 之 声明 2025年三季度持续督导意见 2025年9月15日，张家港悦升科技合伙企业（有限合伙）（以下简称"悦升 科技"）与江苏澳洋健 ...

Investment Rating - The report maintains a "Buy" rating for the medical services industry [6][10][63] Core Views - The medical services sector has experienced a significant decline, with a 2.40% drop this week, underperforming the CSI 300 index by 3.22 percentage points [2][12] - The introduction of policies promoting the integration of artificial intelligence in healthcare is expected to create substantial market opportunities for software and hardware service providers [5][6][62] - The report highlights a clear industrialization blueprint for AI in healthcare, indicating a transformative impact on the medical services sector [6][62] Summary by Sections Industry Performance - The medical services sub-sector index closed at 6859.85 points, down 4.07% this week, while other sub-sectors showed mixed results [2][24] - Notable performers in the medical services sector included Aoyang Health (+5.1%) and Berry Genomics (+3.7%), while companies like Zhaoyan New Drug (-12.2%) and Nanmo Biology (-11.9%) faced significant declines [3][29] Valuation Metrics - The current Price-to-Earnings (PE) ratio for the medical services sector is 32.96X, with a Price-to-Book (PB) ratio of 3.32X [4][30] - The PE ratio has decreased by 3.57X compared to the previous week, and the PB ratio has dropped by 0.13X [4][30] Policy Developments - The Chinese government has issued guidelines to promote the application of AI in healthcare, aiming for widespread implementation by 2030 [5][60][61] - The policy emphasizes the dual focus on regulation and development, benefiting compliant and technologically robust leading enterprises [9][62] Investment Recommendations - The report suggests focusing on high-growth areas such as ADC CDMO and weight-loss drug supply chains, with specific companies like WuXi AppTec and Haoyuan Pharmaceutical highlighted [10][63] - It also recommends monitoring third-party medical testing laboratories and consumer healthcare sectors, particularly in ophthalmology and dentistry [10][63]

Core Insights - The article provides an overview of the latest trends in investment and financing activities in the domestic market, highlighting key sectors and notable companies involved in recent funding rounds and mergers [5][6]. Group 1: Investment Overview - This week, there were 62 disclosed financing events in the domestic primary market, a decrease of 100 events compared to the previous week. The total disclosed financing amount reached 4.069 billion RMB, with an average financing amount of 123 million RMB [7]. - The most active sectors in terms of financing events were intelligent manufacturing (20 events), artificial intelligence (10 events), and healthcare (9 events) [9]. Group 2: Sector Analysis - In terms of disclosed financing amounts, intelligent manufacturing led with a total of approximately 1.149 billion RMB. Notably, "Zhongling Technology," a developer of OLED precision metal masks, completed a 400 million RMB Series C financing round [11]. - The artificial intelligence sector followed with a disclosed financing total of 920 million RMB, where "Agile Medical," focused on surgical robots, secured several hundred million RMB in Series B financing [11]. Group 3: Regional Distribution - The majority of disclosed financing events were concentrated in Jiangsu (16 events), Zhejiang (9 events), and Guangdong (9 events) [15]. - Jiangsu reported a total financing of 670 million RMB across 6 disclosed events, while Zhejiang had 1.229 billion RMB from 7 disclosed events [18]. Group 4: Financing Stages - The distribution of financing events by stage showed 46 early-stage events and 16 growth-stage events [19]. Group 5: Major Financing Events - Significant financing events included "Weneng" raising 670 million RMB in Series C, "Zhongling Technology" raising over 400 million RMB in Series C, and "Xingchen New Energy" raising over 300 million RMB in Series A [23][26][24]. Group 6: Mergers and Acquisitions - There were 16 disclosed completed M&A events this week, an increase of 10 from the previous week, primarily in the healthcare, intelligent manufacturing, and materials sectors. Notably, "Yuanda Environmental" acquired "Wuling Electric Power" for 24.667 billion RMB [51][53].

Core Viewpoint - Jiangsu Aoyang Health Industry Co., Ltd. has completed the transfer of 20% of its shares to Zhangjiagang Yuesheng Technology Partnership, marking a shift from private to local state-owned control, which may enhance its market position and client trust [1][2][3] Group 1: Share Transfer Details - Aoyang Health's original controlling shareholder, Aoyang Group, transferred 20% of its shares, totaling 153 million shares, at a price of 3.87 yuan per share, amounting to a total of 593 million yuan [1] - The transfer was officially completed on November 6, 2025, with the new controlling entity being Zhangjiagang Economic and Technological Development Zone Management Committee [1] Group 2: Financial Performance - In the first three quarters of 2025, Aoyang Health reported a net profit attributable to shareholders of 40.11 million yuan, a year-on-year increase of 3.71% [2] - The net profit for the third quarter reached 8.56 million yuan, a significant increase of 533.86% compared to the same period last year, marking a new high for recent years [2] Group 3: Strategic Implications of Control Change - The change in control to a local state-owned entity may provide Aoyang Health with enhanced credibility and trust from clients, particularly those with government collaboration interests [2] - The new controlling entity's diverse industry background could facilitate resource integration, potentially enhancing Aoyang Health's capabilities in areas like remote healthcare and smart health monitoring [3] - The shift aligns with national policies promoting integrated medical and elderly care, positioning Aoyang Health to leverage new market opportunities and improve competitive advantage [3]

Core Insights - The company has achieved significant growth in profitability, with a net profit of 8.56 million yuan in Q3 2025, marking a substantial increase of 533.86% year-on-year, reaching a new high for the same period in recent years [1] - For the first three quarters of 2025, the cumulative net profit attributable to shareholders reached 40.11 million yuan, reflecting a year-on-year growth of 3.71%, demonstrating strong operational resilience despite short-term revenue adjustments [1] - The company’s core business profitability has improved, with a net profit of 2.35 million yuan in Q3 2025, up 63.23% year-on-year, indicating a substantial enhancement in core business performance [1] Profitability and Efficiency - The gross profit margin for the first three quarters of 2025 remained stable at 14.27%, while the net profit margin in Q3 increased to 1.91%, up 1.57 percentage points year-on-year, showcasing improved profitability quality during revenue structure adjustments [2] - The company has established a medical consortium centered around Aoyang Hospital, with over 2,300 total beds, covering comprehensive medical and rehabilitation services, thus forming a strong competitive advantage in the regional healthcare market [2] Shareholding Changes - The company’s shareholding change has been a focal point, with the controlling shareholder, Aoyang Group, transferring 20% of its shares to Zhangjiagang Yuesheng Technology Co., Ltd. for a total price of 593 million yuan, which has been completed [3] - Following the change in control, the new shareholder is expected to provide policy resource support, expand financing channels, and enhance regional business collaboration, thereby optimizing the company’s governance structure and strengthening its capital base for future development [3]

江苏澳洋健康产业股份有限公司 关于控股股东协议转让股份完成过户登记暨公司控股股东、实际控制人变更的公告 证券代码：002172 证券简称：澳洋健康 公告编号：2025-34 关于控股股东协议转让股份完成过户登记暨公司 控股股东、实际控制人变更的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚 假记载、误导性陈述或者重大遗漏负连带责任。 江苏澳洋健康产业股份有限公司（以下简称"澳洋健康"或"公司"）于 今日收到张家港悦升科技合伙企业（有限合伙）（以下简称"悦升科技"）的通 知，获悉其协议转让公司股份事宜已完成过户登记手续。具体情况如下： 一、本次交易的基本情况 公司原控股股东澳洋集团有限公司（以下简称"澳洋集团"）、实际控制人 沈学如、实际控制人的一致行动人沈卿于 2025 年 9 月 15 日与张家港悦升科技合 伙企业（有限合伙）签署了《股份转让协议》。澳洋集团拟通过协议转让方式转 让公司 20%股份，共计 153,146,472 股。转让价格为 3.87 元/股，合计总金额为 592,676,846.64 元。 本次权益变动不构成关联交易，不触及要约收购。本次权益变动完成后，悦 升科技 ...

Group 1 - The core point of the article is that Aoyang Health announced the release of a portion of shares pledged by its major shareholder, Aoyang Group, amounting to 15,000,000 shares [2] Group 2 - Aoyang Group holds more than 5% of Aoyang Health's shares [2] - The announcement was made on the evening of November 6 [2]

Core Viewpoint - Aoyang Health has completed the transfer of shares to Yue Sheng Technology, resulting in a change of controlling shareholder and actual controller [1] Group 1: Share Transfer Details - Aoyang Health announced that it received notification from Zhangjiagang Yue Sheng Technology Partnership (Limited Partnership) regarding the completion of the share transfer registration [1] - Following the completion of the share transfer, the controlling shareholder of Aoyang Health has changed from Aoyang Group to Yue Sheng Technology [1] - The actual controller of the company has changed from Shen Xueru to the Management Committee of Zhangjiagang Economic and Technological Development Zone [1]

Core Points - The announcement from Aoyang Health indicates a significant change in its ownership structure, with Aoyang Group transferring 20% of its shares to Yuesheng Technology [1] - The share transfer involves 153,146,472 shares at a price of 3.87 yuan per share, totaling approximately 592.68 million yuan [1] - Following the transfer, Yuesheng Technology will hold 20% of the company's total shares, and the controlling shareholder will shift from Aoyang Group to Yuesheng Technology, with the actual controller changing to the Zhangjiagang Economic and Technological Development Zone Management Committee [1] Summary by Sections - **Ownership Change** - Aoyang Group is transferring 20% of its shares to Yuesheng Technology, resulting in a new controlling shareholder [1] - The actual controller will change from Shen Xueru to the Zhangjiagang Economic and Technological Development Zone Management Committee [1] - **Financial Details** - The share transfer involves 153,146,472 shares priced at 3.87 yuan each, amounting to a total of 592,676,846.64 yuan [1] - The transaction does not constitute a related party transaction and does not trigger a mandatory tender offer [1] - **Completion of Transfer** - The transfer of shares has been completed, and the company has received notification of the successful registration of the transfer [1]